North America Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity

North America pharmaceutical manufacturing industry is expected to grow by 11.0% annually in the forecast period and reach $241.76 billion by 2027 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.

Highlighted with 26 tables and 60 figures, this 125-page report “North America Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year because 2020 is not appropriate for research base due to the outbreak of COVID-19. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Industry Structure
Growth Drivers
Restraints and Challenges
Emerging Product Trends & Industry Opportunities
Porter’s Fiver Forces

The trend and outlook of North America industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.

Based on Formulation, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

Tablets
Capsules
Injectable
Sprays
Suspensions
Powders
Other Formulations

Based on Route of Administration, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

Oral Medicine
Topical Medicine
Parenteral Medicine
Inhalations
Other Routes of Administration

Based on Age Group, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

Children & Adolescents
Adults
Geriatric

Based on Therapeutic Application, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

Cardiovascular Diseases
Pain
Diabetes
Cancer
Respiratory Diseases
Neurological Diseases
Orthopedics
Other Applications

Based on Drug Type, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

Branded Prescription Drugs
Generic Prescription Drugs
OTC Drugs

Based on Distribution Channels, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

Retail Channels
Non-retail Channels

Based on Manufacturing Facility, the North America industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.

In-house Facility
Outsourced Facility

Geographically, the following national/local markets are fully investigated:

U.S.
Canada
Mexico

For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players.

Specifically, potential risks associated with investing in North America pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through a proprietary Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):

Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co. Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Frequently Asked Questions about the North American Pharmaceutical Manufacturing Industry

What is the estimated value of the North American Pharmaceutical Manufacturing Industry?

The North American Pharmaceutical Manufacturing Industry was estimated to be valued at $116610 Million in 2020.

What is the growth rate of the North American Pharmaceutical Manufacturing Industry?

The growth rate of the North American Pharmaceutical Manufacturing Industry is 11.0%, with an estimated value of $241758.7 Million by 2027.

What is the forecasted size of the North American Pharmaceutical Manufacturing Industry?

The North American Pharmaceutical Manufacturing Industry is estimated to be worth $241758.7 Million by 2027.

Who are the key companies in the North American Pharmaceutical Manufacturing Industry?

Key companies in the North American Pharmaceutical Manufacturing Industry include Abbott Laboratories, Aenova Group, Amgen, AstraZeneca, Catalent Inc., Eli Lilly and Company, F. Hoffmann, La Roche Ltd., Gilead Sciences and GlaxoSmithKline PLC.

Report Attribute	Details
No. of Pages	125
Published	March 2021
Forecast Period	2020 - 2027
Estimated Market Value ( USD ) in 2020	$ 116610 Million
Forecasted Market Value ( USD ) by 2027	$ 241758.7 Million
Compound Annual Growth Rate	11.0%
Regions Covered	North America

1 Introduction

1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Industry Research Methodology
1.2.2 Industry Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Industry Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Industry Overview and Dynamics

2.1 Industry Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Industry
2.2 Major Growth Drivers
2.3 Industry Restraints and Challenges
2.4 Emerging Opportunities and Industry Trends
2.5 Porter’s Fiver Forces Analysis

3 Segmentation of North America Industry by Formulation

3.1 Industry Overview by Formulation
3.2 Tablets
3.3 Capsules
3.4 Injectable
3.5 Sprays
3.6 Suspensions
3.7 Powders
3.8 Other Formulations

4 Segmentation of North America Industry by Route of Administration

4.1 Industry Overview by Route of Administration
4.2 Oral Medicine
4.3 Topical Medicine
4.4 Parenteral Medicine
4.5 Inhalations
4.6 Other Routes of Administration

5 Segmentation of North America Industry by Age Group

5.1 Industry Overview by Age Group
5.2 Children & Adolescents
5.3 Adults
5.4 Geriatric

6 Segmentation of North America Industry by Therapeutic Application

6.1 Industry Overview by Therapeutic Application
6.2 Cardiovascular Diseases
6.3 Pain
6.4 Diabetes
6.5 Cancer
6.6 Respiratory Diseases
6.7 Neurological Diseases
6.8 Orthopedics
6.9 Other Applications

7 Segmentation of North America Industry by Drug Type

7.1 Industry Overview by Drug Type
7.2 Branded Prescription Drugs
7.3 Generic Prescription Drugs
7.4 OTC Drugs

8 Segmentation of North America Industry by Distribution Channels

8.1 Industry Overview by Distribution Channels
8.2 Retail Channels
8.3 Non-retail Channels

9 Segmentation of North America Industry by Manufacturing Facility

9.1 Industry Overview by Manufacturing Facility
9.2 In-house Facility
9.3 Outsourced Facility

10 North America Industry 2020-2027 by Country

10.1 Overview of North America Industry
10.2 U.S.
10.3 Canada
10.4 Mexico

11 Competitive Landscape

11.1 Overview of Key Vendors
11.2 New Product Launch, Partnership, Investment, and M&A
11.3 Company Profiles

Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda

12 Investing in North America Industry: Risk Assessment and Management

12.1 Risk Evaluation of North America Industry
12.2 Critical Success Factors (CSFs)

Related Reports and Products

List of Tables

Table 1. Snapshot of North America Pharmaceutical Manufacturing Industry in Balanced Perspective, 2020-2027
Table 2. Growth Rate of World Real GDP, 2017-2021
Table 3. Main Product Trends and Industry Opportunities in North America Pharmaceutical Manufacturing Industry
Table 4. North America Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 5. North America Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 6. North America Pharmaceutical Manufacturing Industry by Age Group, 2017-2027, $ bn
Table 7. North America Pharmaceutical Manufacturing Industry by Therapeutic Application, 2017-2027, $ bn
Table 8. North America Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 9. North America Pharmaceutical Manufacturing Industry by Distribution Channels, 2017-2027, $ bn
Table 10. North America Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2017-2027, $ bn
Table 11. North America Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn
Table 12. U.S. Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 13. U.S. Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 14. U.S. Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 15. Canada Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 16. Canada Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 17. Canada Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 18. Mexico Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn
Table 19. Mexico Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn
Table 20. Mexico Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn
Table 21. Abbott Laboratories: Company Snapshot
Table 22. Abbott Laboratories: Business Segmentation
Table 23. Abbott Laboratories: Product Portfolio
Table 24. Abbott Laboratories: Revenue, 2017-2019, $ bn
Table 25. Risk Evaluation for Investing in North America Industry, 2020-2027
Table 26. Critical Success Factors and Key Takeaways

List of Figures

Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Industry Estimation
Figure 4. North America Industry Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027
Figure 5. North America Pharmaceutical Manufacturing Industry, 2017-2027, $ bn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of North America Pharmaceutical Manufacturing Industry
Figure 8. Primary Restraints and Impact Factors of North America Pharmaceutical Manufacturing Industry
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Fiver Forces Analysis of North America Pharmaceutical Manufacturing Industry
Figure 11. Breakdown of North America Pharmaceutical Manufacturing Industry by Formulation, 2020-2027, % of Revenue
Figure 12. Contribution to North America 2021-2027 Cumulative Revenue by Formulation, Value ($ bn) and Share (%)
Figure 13. North America Pharmaceutical Manufacturing Industry: Tablets, 2017-2027, $ bn
Figure 14. North America Pharmaceutical Manufacturing Industry: Capsules, 2017-2027, $ bn
Figure 15. North America Pharmaceutical Manufacturing Industry: Injectable, 2017-2027, $ bn
Figure 16. North America Pharmaceutical Manufacturing Industry: Sprays, 2017-2027, $ bn
Figure 17. North America Pharmaceutical Manufacturing Industry: Suspensions, 2017-2027, $ bn
Figure 18. North America Pharmaceutical Manufacturing Industry: Powders, 2017-2027, $ bn
Figure 19. North America Pharmaceutical Manufacturing Industry: Other Formulations, 2017-2027, $ bn
Figure 20. Breakdown of North America Pharmaceutical Manufacturing Industry by Route of Administration, 2020-2027, % of Revenue
Figure 21. Contribution to North America 2021-2027 Cumulative Revenue by Route of Administration, Value ($ bn) and Share (%)
Figure 22. North America Pharmaceutical Manufacturing Industry: Oral Medicine, 2017-2027, $ bn
Figure 23. North America Pharmaceutical Manufacturing Industry: Topical Medicine, 2017-2027, $ bn
Figure 24. North America Pharmaceutical Manufacturing Industry: Parenteral Medicine, 2017-2027, $ bn
Figure 25. North America Pharmaceutical Manufacturing Industry: Inhalations, 2017-2027, $ bn
Figure 26. North America Pharmaceutical Manufacturing Industry: Other Routes of Administration, 2017-2027, $ bn
Figure 27. Breakdown of North America Pharmaceutical Manufacturing Industry by Age Group, 2020-2027, % of Revenue
Figure 28. Contribution to North America 2021-2027 Cumulative Revenue by Age Group, Value ($ bn) and Share (%)
Figure 29. North America Pharmaceutical Manufacturing Industry: Children & Adolescents, 2017-2027, $ bn
Figure 30. North America Pharmaceutical Manufacturing Industry: Adults, 2017-2027, $ bn
Figure 31. North America Pharmaceutical Manufacturing Industry: Geriatric, 2017-2027, $ bn
Figure 32. Breakdown of North America Pharmaceutical Manufacturing Industry by Therapeutic Application, 2020-2027, % of Revenue
Figure 33. Contribution to North America 2021-2027 Cumulative Revenue by Therapeutic Application, Value ($ bn) and Share (%)
Figure 34. North America Pharmaceutical Manufacturing Industry: Cardiovascular Diseases, 2017-2027, $ bn
Figure 35. North America Pharmaceutical Manufacturing Industry: Pain, 2017-2027, $ bn
Figure 36. North America Pharmaceutical Manufacturing Industry: Diabetes, 2017-2027, $ bn
Figure 37. North America Pharmaceutical Manufacturing Industry: Cancer, 2017-2027, $ bn
Figure 38. North America Pharmaceutical Manufacturing Industry: Respiratory Diseases, 2017-2027, $ bn
Figure 39. North America Pharmaceutical Manufacturing Industry: Neurological Diseases, 2017-2027, $ bn
Figure 40. North America Pharmaceutical Manufacturing Industry: Orthopedics, 2017-2027, $ bn
Figure 41. North America Pharmaceutical Manufacturing Industry: Other Applications, 2017-2027, $ bn
Figure 42. Breakdown of North America Pharmaceutical Manufacturing Industry by Drug Type, 2020-2027, % of Revenue
Figure 43. Contribution to North America 2021-2027 Cumulative Revenue by Drug Type, Value ($ bn) and Share (%)
Figure 44. North America Pharmaceutical Manufacturing Industry: Branded Prescription Drugs, 2017-2027, $ bn
Figure 45. North America Pharmaceutical Manufacturing Industry: Generic Prescription Drugs, 2017-2027, $ bn
Figure 46. North America Pharmaceutical Manufacturing Industry: OTC Drugs, 2017-2027, $ bn
Figure 47. Breakdown of North America Pharmaceutical Manufacturing Industry by Distribution Channels, 2020-2027, % of Revenue
Figure 48. Contribution to North America 2021-2027 Cumulative Revenue by Distribution Channels, Value ($ bn) and Share (%)
Figure 49. North America Pharmaceutical Manufacturing Industry: Retail Channels, 2017-2027, $ bn
Figure 50. North America Pharmaceutical Manufacturing Industry: Non-retail Channels, 2017-2027, $ bn
Figure 51. Breakdown of North America Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2020-2027, % of Revenue
Figure 52. Contribution to North America 2021-2027 Cumulative Revenue by Manufacturing Facility, Value ($ bn) and Share (%)
Figure 53. North America Pharmaceutical Manufacturing Industry: In-house Facility, 2017-2027, $ bn
Figure 54. North America Pharmaceutical Manufacturing Industry: Outsourced Facility, 2017-2027, $ bn
Figure 55. Breakdown of North America Pharmaceutical Manufacturing Industry by Country, 2020 and 2027, % of Revenue
Figure 56. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 57. U.S. Pharmaceutical Manufacturing Industry, 2017-2027, $ bn
Figure 58. Canada Pharmaceutical Manufacturing Industry, 2017-2027, $ bn
Figure 59. Pharmaceutical Manufacturing Industry in Mexico, 2017-2027, $ bn
Figure 60. Growth Stage of North America Industrial Robot Software Industry over the Forecast Period

Samples

LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline PLC
Johnson & Johnson
Lonza Group
Lupin
Merck & Co. Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi S.A.
Takeda

Methodology

LOADING...